Newsletter Sign Up

StopAfib.org

Newsletter Signup
Get in Rhythm. Stay in Rhythm.™ View Replays from Atrial Fibrillation Patient Conference Aug 4-6, 2017, in Dallas, TX
Get in Rhythm. Stay in Rhythm.™ View Replays from Atrial Fibrillation Patient Conference Aug 4-6, 2017, in Dallas, TX

FDA Approves Genetic Lab Test for Warfarin Sensitivity

Good news for afib patients likely to go on warfarin

September 17, 2007 6:20 AM CT

The U.S. Food and Drug Administration approved a genetic test, the Nanosphere Verigene Warfarin Metabolism Nucleic Acid Test, that helps doctors identify whether a patient is especially sensitive to warfarin (Coumadin®).

One-third of patients receiving warfarin to prevent blood clots metabolize it differently than expected and have a higher risk of bleeding, some of which may be due to variants of two genes, CYP2C9 and VKORC1, which are detected by this test.

Warfarin is a very difficult drug, and according to the FDA is the second most common drug involved in emergency room visits for adverse drug events.

See FDA News Release: FDA Clears Genetic Lab Test for Warfarin Sensitivity

Back to News

Last Modified September 17, 2007

Get Started Learning About Atrial Fibrillation

Afib Community

Blog Forum

Locate Help

Afib services near you

USA Locations International Locations List Your Afib Services

We comply with the HONcode standard for trustworthy health information: verify here.

Newsletter Sign Up